297 related items for PubMed ID: 18930517
1. Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease.
Abe J, Ebata R, Jibiki T, Yasukawa K, Saito H, Terai M.
J Allergy Clin Immunol; 2008 Nov; 122(5):1008-1013.e8. PubMed ID: 18930517
[Abstract] [Full Text] [Related]
2. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[Abstract] [Full Text] [Related]
3. Osteoprotegerin serum levels in Kawasaki disease: an additional potential marker in predicting children with coronary artery involvement.
Simonini G, Masi L, Giani T, Piscitelli E, Cimaz R, Vierucci S, Brandi ML, Falcini F.
J Rheumatol; 2005 Nov; 32(11):2233-8. PubMed ID: 16265708
[Abstract] [Full Text] [Related]
4. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM, Silverman ED, McCrindle BW, Yeung RS.
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[Abstract] [Full Text] [Related]
5. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
Khowsathit P, Hong-Hgam C, Khositseth A, Wanitkun S.
J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
[Abstract] [Full Text] [Related]
6. Immunoglobulin failure and retreatment in Kawasaki disease.
Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C.
Pediatr Cardiol; 2003 Nov; 24(2):145-8. PubMed ID: 12457253
[Abstract] [Full Text] [Related]
7. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa H.
Pediatr Infect Dis J; 2008 Feb; 27(2):155-60. PubMed ID: 18174868
[Abstract] [Full Text] [Related]
8. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease.
Wang Y, Wang W, Gong F, Fu S, Zhang Q, Hu J, Qi Y, Xie C, Zhang Y.
Arthritis Rheum; 2013 Mar; 65(3):805-14. PubMed ID: 23440694
[Abstract] [Full Text] [Related]
9. The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease.
Kuo HC, Yang KD, Liang CD, Bong CN, Yu HR, Wang L, Wang CL.
Pediatr Allergy Immunol; 2007 Jun; 18(4):354-9. PubMed ID: 17584314
[Abstract] [Full Text] [Related]
10. Assessment of intravenous immunoglobulin non-responders in Kawasaki disease.
Hwang JY, Lee KY, Rhim JW, Youn YS, Oh JH, Han JW, Lee JS, Burgner D.
Arch Dis Child; 2011 Nov; 96(11):1088-90. PubMed ID: 20551193
[Abstract] [Full Text] [Related]
11. Treatment of Kawasaki disease using locally product intravenous immunoglobulin.
Sangtawesin C, Kirawitaya T, Layangkool T, Nawasiri W, Vimolsarawong N.
J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S656-60. PubMed ID: 14700163
[Abstract] [Full Text] [Related]
12. High-dose intravenous immunoglobulin downregulates the activated levels of inflammatory indices except erythrocyte sedimentation rate in acute stage of Kawasaki Disease.
Lee KY, Lee HS, Hong JH, Han JW, Lee JS, Whang KT.
J Trop Pediatr; 2005 Apr; 51(2):98-101. PubMed ID: 15677370
[Abstract] [Full Text] [Related]
13. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset.
Fukunishi M, Kikkawa M, Hamana K, Onodera T, Matsuzaki K, Matsumoto Y, Hara J.
J Pediatr; 2000 Aug; 137(2):172-6. PubMed ID: 10931407
[Abstract] [Full Text] [Related]
14. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12.
Wittkowski H, Hirono K, Ichida F, Vogl T, Ye F, Yanlin X, Saito K, Uese K, Miyawaki T, Viemann D, Roth J, Foell D.
Arthritis Rheum; 2007 Dec; 56(12):4174-81. PubMed ID: 18050248
[Abstract] [Full Text] [Related]
15. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y.
Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
[Abstract] [Full Text] [Related]
16. Intravenous immunoglobulin does not increase FcgammaRIIB expression on monocytes/macrophages during acute Kawasaki disease.
Ichiyama T, Ueno Y, Hasegawa M, Ishikawa Y, Matsubara T, Furukawa S.
Rheumatology (Oxford); 2005 Mar; 44(3):314-7. PubMed ID: 15572393
[Abstract] [Full Text] [Related]
17. Initial intravenous gamma-globulin treatment failure in Iranian children with Kawasaki disease.
Kashef S, Safari M, Amin R.
Kaohsiung J Med Sci; 2005 Sep; 21(9):401-4. PubMed ID: 16248123
[Abstract] [Full Text] [Related]
18. [Biomarkers associated with unresponsiveness to IVIG in children with Kawasaki disease].
Abe J, Matsuda A.
Nihon Rinsho Meneki Gakkai Kaishi; 2013 Sep; 36(1):27-34. PubMed ID: 23445729
[Abstract] [Full Text] [Related]
19. Association of lower eosinophil-related T helper 2 (Th2) cytokines with coronary artery lesions in Kawasaki disease.
Kuo HC, Wang CL, Liang CD, Yu HR, Huang CF, Wang L, Hwang KP, Yang KD.
Pediatr Allergy Immunol; 2009 May; 20(3):266-72. PubMed ID: 19438983
[Abstract] [Full Text] [Related]
20. [Value of serum soluble interleukin-2R, interleukin-6 and C-reactive protein in the early diagnosis of Kawasaki disease].
Peng Q, Wu Q, Chen CH, Hong H, Zhang LY.
Zhongguo Dang Dai Er Ke Za Zhi; 2006 Jun; 8(3):208-10. PubMed ID: 16787593
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
